Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Read more about Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states.
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Read more about The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Decoding non-canonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1α. Read more about Decoding non-canonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1α.
Ciliary Hedgehog signaling patterns the digestive system to generate mechanical forces driving elongation. Read more about Ciliary Hedgehog signaling patterns the digestive system to generate mechanical forces driving elongation.
Viral evasion of the integrated stress response through antagonism of eIF2-P binding to eIF2B. Read more about Viral evasion of the integrated stress response through antagonism of eIF2-P binding to eIF2B.
Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children. Read more about Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children.
The reduction of race and gender bias in clinical treatment recommendations using clinician peer networks in an experimental setting. Read more about The reduction of race and gender bias in clinical treatment recommendations using clinician peer networks in an experimental setting.
Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses. Read more about Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses.
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer. Read more about RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Read more about Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
